Treatment-resistant depression: Understandings on the neurobiological etiology that lead to novel pharmacological treatment options

Eunsoo Won, Byoung Joo Ham, Yong Ku Kim

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Treatment-resistant depression (TRD) places a great burden not only to patients but society as a whole. A deep understanding of the neurobiological etiology of TRD will aid us to develop effective treatment strategies for TRD. In this chapter, we will discuss the recent findings on neurobiological mechanisms underlying TRD and corresponding novel pharmacological treatment strategies. Genetics and interactions with environmental factors; alterations in neural substrates, neuroinflammatory conditions, and glutamatergic neurotransmission; and glial cell pathology have been discussed. Anti-inflammatory drugs and ketamine have been suggested as novel treatment agents for TRD. Future studies that investigate the long-term efficacies and safety of such new treatment options in TRD are needed.

Original languageEnglish
Title of host publicationTreatment Resistance in Psychiatry
Subtitle of host publicationRisk Factors, Biology, and Management
PublisherSpringer Singapore
Pages99-107
Number of pages9
ISBN (Electronic)9789811043581
ISBN (Print)9789811043574
DOIs
Publication statusPublished - 2018 Jan 1

Keywords

  • Neurobiological etiology
  • Novel pharmacological treatment option
  • Treatment-resistant depression

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Treatment-resistant depression: Understandings on the neurobiological etiology that lead to novel pharmacological treatment options'. Together they form a unique fingerprint.

Cite this